August 12, 2019
This feature highlights changes in clinical research organizations’ personnel.
Accelerate Diagnostics has named Jack Phillips chief operating officer. Phillips previously served as president and chief executive officer at Roche Diagnostics.
Rafael Amado has been appointed executive vice president of research and development and chief medical officer at Allogene Therapeutics. Amado was most recently president of research and development at Adaptimmune.
Beatrice Setnik has been named chief scientific officer at Altasciences. Setnik was previously vice president, scientific and medical affairs, at Syneos Health.
Aprea Therapeutics has named Scott Coiante senior vice president and chief financial officer. Coiante was previously senior vice president and CFO at Agile Therapeutics.
Assembly Biosciences has named John McHutchison president and chief executive officer. McHutchison most recently served as chief scientific officer and head of research and development at Gilead Sciences.
David Fryrear has been named senior vice president and head of the clinical research and quality assurance organization at Astellas. Fryrear was previously senior director, R&D quality assurance — clinical, PV, RA and knowledge management at AbbVie.
Carl St. Bernard has been appointed president and chief executive officer of CeloNova Biosciences. St. Bernard was previously president and CEO of Tryton Medical.
Amy Burroughs has been appointed chief executive officer and Scott Harris has been named chief operating officer at Cleave Therapeutics. Burroughs was most recently executive-in-residence at 5AM Ventures and a strategic commercial advisor to Crinetics Pharmceuticals. Harris was most recently executive vice president, corporate development and operations, at Navire Pharma.
Codexis has appointed Ross Taylor as senior vice president and chief financial officer, effective August 19. Taylor was previously CFO at Abaxis, Inc.
Crucial Data Solutions
Jeff Rogers has been named president at Crucial Data Solutions. Rogers was most recently chief commercial officer at Trialbee.
Emalex Biosciences has named Atul Mahableshwarkar senior vice president of drug development. Mahableshwarkar is a board-certified adult psychiatrist and was formerly an associate professor and vice chair of the Department of Psychiatry and Behavioral Sciences at the Chicago Medical School of Rosalind Franklin University.
Priti Hegde has been named chief scientific officer at Foundation Medicine. Hegde was most recently senior director and principal scientist in oncology biomarker development at Genentech.
Kimberly Southern has been appointed chief operating officer at Glauconix Biosciences. Southern was previously COO at New England Peptide.
Bruce Colwill has been appointed chief financial officer at InMed Pharmaceuticals. Colwill was previously chief financial officer at General Fusion.
Bret Boudousquie has been appointed chief executive officer at Nimbus. Boudousquie was previously president of RadiaDyne.
Palladio Biosciences has named Alex Martin chief executive officer. Martin most recently served as CEO of Realm Therapeutics.
Parexel has announced the appointment of Gavin Nichols as executive vice president, informatics and information technology. Nichols was formerly chief information officer and executive vice president of technology at BioClinica.
PROMETRIKA has named Barry Mirrer as head of quality assurance. Mirrer was previously global head, quality management, for IQVIA.
Alfredo Galvez has been appointed chief scientific advisor at Reliv International. Galvez was formerly CSO at SL Tech, a Reliv subsidiary.
Sudha Parasuraman has been named chief financial officer and Edward “Tad” Stewart has been appointed chief business officer at Ribon Therapeutics. Parasuraman was most recently CMO for X4 Pharmaceuticals. Stewart previously served as CBO for Crescendo Biologics.
Rodin Therapeutics has named Ajim Tamboli as chief financial officer. Tamboli most recently focused on life sciences investing at Asymmetry Capital Management.
Noah Nasser has been named chief executive officer at Serimmune. Nasser previously was chief commercial officer at San Diego biotechnology company, Human Longevity.
Silence Therapeutics has announced that Jørgen Wittendorff has been named head of manufacturing. Wittendorff most recently served as senior director, CMC manufacturing and product supply at Ablynx.
SQZ Biotech has appointed Teri Loxam chief financial officer. Loxam was previously senior vice president of investor relations and global communications at Merck & Co.
Veravas has announced the appointment of Carroll Streetman as chief executive officer. Streetman was previously global vice president and chief marketing officer, oncology, at Eli Lilly.
Robert Ang has been appointed president and chief executive officer at Vor Biopharma. Ang is the former chief business officer of Neon Therapeutics.
Worldwide Clinical Trials
Worldwide Clinical Trials has named Hiromi Wakita vice president of clinical operations. Wakita will lead the company’s operations in Japan. He previously held the position of Japan general manager for Clinipace.